Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Short-term Mental Health Changes Seen in Mothers and Play-age Children after the 2023 Türkiye-Syria Earthquakes.

Disaster medicine and public health preparedness·2026
Same author

The impact of systemic iron overload on retinal and choroidal microcirculation in transfusion-dependent beta-thalassemia patients.

BMC ophthalmology·2026
Same author

Leukapheresis, rasburicase, and acute complications of hyperleukocytosis in pediatric leukemia: A retrospective cohort study.

Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis·2026
Same author

The Impact of L-asparaginase Hypersensitivity and Desensitization in Children with Acute Lymphoblastic Leukemia.

International archives of allergy and immunology·2026
Same author

A Descriptive Preanalytical Survey of Procedures Followed for the Screening of Glucose Dysregulation in Thalassemia Centers: Implications for Clinical Practice and Call for Harmonization.

Mediterranean journal of hematology and infectious diseases·2026
Same author

Characterization of ferroportin disease and SLC40A1-related hemochromatosis - Results from the EASL non-HFE registry.

Journal of hepatology·2026

Related Experiment Video

Updated: Jun 6, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Antihyperlipidemic agents cause a decrease in von Willebrand factor levels in pediatric patients with familial

S Songül Yalçin1, Bülent Güneş, Sule Unal

  • 1Hacettepe University Faculty of Medicine Department ofPediatrics, 06100, Ankara, Turkey. siyalcin@hacettepe.edu.tr

Journal of Pediatric Endocrinology & Metabolism : JPEM
|November 16, 2010
PubMed
Summary

Familial hyperlipidemia patients on antihyperlipidemic agents showed lower plasma von Willebrand factor antigen (vWf:Ag) levels. Early treatment may reduce atherosclerotic risk by lowering both lipid levels and vWf:Ag.

More Related Videos

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Related Experiment Videos

Last Updated: Jun 6, 2026

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation
08:30

Investigating von Willebrand Factor Pathophysiology Using a Flow Chamber Model of von Willebrand Factor-platelet String Formation

Published on: August 14, 2017

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation
06:47

Isolation and Analysis of Plasma Lipoproteins by Ultracentrifugation

Published on: January 28, 2021

Area of Science:

  • Cardiovascular Genetics
  • Pediatric Endocrinology

Background:

  • Familial hyperlipidemia is a genetic disorder increasing atherosclerosis risk.
  • Hyperlipidemia contributes to atherosclerotic events via endothelial damage.

Purpose of the Study:

  • To measure plasma fibrinogen and von Willebrand factor antigen (vWf:Ag) in pediatric familial hyperlipidemia patients.
  • To investigate the impact of serum lipid levels and antihyperlipidemic agents on these parameters.

Main Methods:

  • Analysis of 41 pediatric patients with familial hyperlipidemias.
  • Measurement of plasma vWf:Ag levels in patients receiving antihyperlipidemic agents versus those not.

Main Results:

  • vWf:Ag levels were significantly lower in patients receiving antihyperlipidemic agents (102 +/- 19%) compared to non-receivers (132 +/- 51%, p = 0.010).
  • No specific mention of fibrinogen levels in the results summary.

Conclusions:

  • Early initiation of antihyperlipidemic therapy in familial hyperlipidemia may reduce future atherosclerotic event risk.
  • This risk reduction may be achieved by decreasing both serum lipid levels and plasma vWf:Ag levels.